SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 18th, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 14, 2019, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, FL 33025 (the “Company”), and AUCTUS FUND, LLC, a Delaware limited liability company, with its address at 545 Boylston Street, 2nd Floor, Boston, MA 02116 (the “Buyer”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 18th, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • Nevada
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of August 14, 2019, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation (the "Company"), and AUCTUS FUND, LLC, a Delaware limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the securities purchase agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").
NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Common Stock Purchase Warrant • February 18th, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • Nevada
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the $1,100,000.00 convertible promissory note to the Holder (as defined below) of even date) (the “Note”), Auctus Fund, LLC, a Delaware limited liability company (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to 62,857 shares of Common Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated August 14, 2019, by and among t
EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • February 18th, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • Kansas
THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of December 6, 2019 (the “Execution Date”), by and between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and Oasis Capital, LLC, a Puerto Rico limited liability company (the “Investor”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 18th, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • Kansas
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 25, 2019 (the “Execution Date”), is entered into by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation (the “Company”), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Equity Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
PURCHASE AGREEMENTPurchase Agreement • February 18th, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • Virgin Islands
This Purchase Agreement (“Agreement”) is made and entered into on December 9, 2019 (“Effective Date”), by and between Generex Biotechnology Corporation, a Delaware corporation (“Company”), and the investor whose name appears on the signature page hereto (“Investor”).
